Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER PRESENTED AT 2025 ASCO ANNUAL MEETING2025.06.03
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 20252025.06.02
-
VOLUNTARY ANNOUNCEMENT2025.05.29
-
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I STUDY OF TQB2102 (BISPECIFIC ANTI-HER2 ADC) PRESENTED AT 2025 ASCO ANNUAL MEETING2025.05.27
-
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB FOR FIRST-LINE TREATMENT OF SQ-NSCLC PRESENTED IN 2025 ASCO ANNUAL MEETING2025.05.23
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 20252025.05.06
-
2024 ANNUAL REPORT2025.04.29
-
GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; ADOPTION OF THE NEW ARTICLES; AND NOTICE OF ANNUAL GENERAL MEETING2025.04.29